EMEA-001588-PIP03-18
Key facts
| Invented name |
Braftovi
|
| Active substance |
Encorafenib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0049/2019
|
| PIP number |
EMEA-001588-PIP03-18
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of colorectal carcinoma
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Pierre Fabre Médicament
Tel. +33 800326326
E-mail: medical_information@pierre-fabre.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|